Research in social & administrative pharmacy : RSAP · 2025
Impact of PROMPT questionnaire-based pharmaceutical care on pharmaceutical therapy and health-related quality of life in non-dialysis chronic kidney disease patients: A randomized controlled trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wanpen Paphawee, Sakthong Phantipa
Аннотация
BACKGROUND: Data on the effects of pharmaceutical care (PC) on pharmaceutical therapy-related quality of life and health-related quality of life (HRQoL) in chronic kidney disease (CKD) patients not receiving renal replacement therapy (RRT) remain limited and unclear.
AIM: This study aimed to investigate the effects of PC using the Patient-Reported Outcomes Measure of Pharmaceutical Therapy (PROMPT) questionnaire on medication-related quality of life and HRQoL, assessed through the PROMPT and Kidney Disease Quality of Life (KDQOL) questionnaires, respectively. Additionally, the study compared the sensitivity of these two tools to detect changes resulting from PC provision.
METHODS: A multicenter, single-blinded, parallel randomized controlled trial was conducted at two community hospitals between November 2021 and August 2022. A total of 292 participants were randomized into two groups: the usual care (UC) group (N = 144) and the pharmaceutical care using the PROMPT questionnaire (PCP) group (N = 148). The sensitivity of the two measures to PC provision were evaluated using standardized mean differences (SMDs).
RESULTS: The PCP group demonstrated significantly better scores than the UC group in three out of eight PROMPT dimensions (p < 0.001, p = 0.004, and p = 0.015, respectively) and a higher total PROMPT score (p < 0.001). For the KDQOL, the PCP group showed significant improvement in one out of ten dimensions (p = 0.009). The SMDs for the three significant PROMPT dimensions and total score ranged from 0.28 to 2.10, indicating moderate to large effect sizes, whereas the SMD for the single significant KDQOL dimension was 0.30, indicating a moderate effect size.
CONCLUSION: Pharmaceutical care combined with the use of the PROMPT questionnaire had a positive impact on the quality of life of non-dialysis CKD patients, particularly in pharmaceutical therapy-related aspects. Furthermore, the PROMPT questionnaire exhibited greater sensitivity to the effects of pharmaceutical care compared to the KDQOL.
AIM: This study aimed to investigate the effects of PC using the Patient-Reported Outcomes Measure of Pharmaceutical Therapy (PROMPT) questionnaire on medication-related quality of life and HRQoL, assessed through the PROMPT and Kidney Disease Quality of Life (KDQOL) questionnaires, respectively. Additionally, the study compared the sensitivity of these two tools to detect changes resulting from PC provision.
METHODS: A multicenter, single-blinded, parallel randomized controlled trial was conducted at two community hospitals between November 2021 and August 2022. A total of 292 participants were randomized into two groups: the usual care (UC) group (N = 144) and the pharmaceutical care using the PROMPT questionnaire (PCP) group (N = 148). The sensitivity of the two measures to PC provision were evaluated using standardized mean differences (SMDs).
RESULTS: The PCP group demonstrated significantly better scores than the UC group in three out of eight PROMPT dimensions (p < 0.001, p = 0.004, and p = 0.015, respectively) and a higher total PROMPT score (p < 0.001). For the KDQOL, the PCP group showed significant improvement in one out of ten dimensions (p = 0.009). The SMDs for the three significant PROMPT dimensions and total score ranged from 0.28 to 2.10, indicating moderate to large effect sizes, whereas the SMD for the single significant KDQOL dimension was 0.30, indicating a moderate effect size.
CONCLUSION: Pharmaceutical care combined with the use of the PROMPT questionnaire had a positive impact on the quality of life of non-dialysis CKD patients, particularly in pharmaceutical therapy-related aspects. Furthermore, the PROMPT questionnaire exhibited greater sensitivity to the effects of pharmaceutical care compared to the KDQOL.